BlackRock Health Sciences Trust II logo

BlackRock Health Sciences Trust II(BMEZ)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 117 days
PROFIT SINCE LAST BUY
+22.98% ▲
LAST CLOSE
$17.18
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BMEZ

11/13/2026: BMEZ (2-star) has a low Upturn Star Rating. Not recommended to BUY.

BlackRock Health Sciences Trust II is a closed-end management investment fund that provides exposure to global healthcare and life sciences equities alongside an option-writing income strategy. The fund benefits from BlackRock's institutional research capabilities and secular demographic tailwinds supporting medical innovation. However, it faces risks related to healthcare regulatory changes, sector concentration, and potential market-price discounts to its net asset value. It is well-suited for income-oriented investors seeking targeted healthcare exposure through professional management. Key developments to monitor include distribution coverage stability and fluctuations in the fund's discount to NAV.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile it invests in innovative healthcare and biotech growth companies, its closed-end structure and income focus dilute pure capital appreciation.
Momentum investorWeak fitThe fund moves sluggishly compared to individual momentum stocks due to its diversified multi-asset holdings and discount volatility.
Value investorStrong fit while signal remains positivePurchasing shares at a wide discount to net asset value can offer an attractive margin of safety for value-oriented buyers.
Dividend investorStrong fitThe fund targets regular distribution income derived from portfolio dividends and option premium strategies.
Low-risk investorWeak fitHigh sector concentration in healthcare and biotech introduces significant clinical trial and regulatory volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highThe fund experiences swings driven by both healthcare stock fluctuations and shifts in its market-price premium or discount to NAV.
Valuation riskMediumBuying shares when the discount to NAV narrows or turns into a premium can reduce prospective total returns.
Competition risk (name the main competitor theme, e.g. AI competition)MediumAlternative healthcare closed-end funds and low-fee sector ETFs compete directly for investor capital and yield seekers.
Business qualityStrongThe fund provides professional management backed by BlackRock's institutional framework and rigorous research capabilities.
Dividend incomeMedium / highDistributions depend on option premiums and realized gains, which can vary depending on market conditions.
Execution riskMediumPortfolio managers must successfully navigate complex clinical readouts and regulatory approvals across individual holdings.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.07B USD
Price to earnings Ratio 5.07
1Y Target Price -
Price to earnings Ratio 5.07
1Y Target Price -
Volume (30-day avg) 168.5K shares
Beta -
52 Weeks Range 12.95 - 17.85
Updated Date 11/15/2026
52 Weeks Range 12.95 - 17.85
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 3.39

Sector & Industry Intelligence

Sector

Financial Services

Constructive
Sentiment
Bullish
Momentum
BUY Breadth Improving
BUY participation
50.4%
Active BUY / eligible
61 / 121
30-Day BUY Count Change
+45
Market state
Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Asset Management

BUY participation
52.9%
Active BUY / eligible
9 / 17
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Very Smooth
PRICE STABILITY

Very Smooth

The stock has followed a highly orderly price path with minimal short-term disruption.

Analysis of Past Performance

Type Stock
Historic Profit 45.97%
Avg. Invested days 84
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BMEZ receives a 3-star rating, supported by solid unit economics. The rating is constrained by soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
BMEZ has moderate overall fundamentals (3 stars), with moderate financial health, strong growth momentum, and soft ownership. In FY2024 versus FY2023, solid earnings growth (+17.2%) and strong cash generation (FCF margin 272.2%) are partially offset by very low insider ownership of 0.02%.

Financial Health Rating

★★★★★
BMEZ's financial health is supported by solid cash strength, including free-cash-flow generation (272.2% of revenue). Operating efficiency is moderate (3 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is BMEZ's strongest growth driver at +193.8% FY2024 versus FY2023 (strong, 5 stars). Earnings growth (+17.2%, solid) and free-cash-flow growth (+104.6%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 28.2% (moderate) and 0.0% of outstanding shares are publicly tradable (soft). Insider ownership is only 0.02%, which materially reduces the ownership score.

Unit Economics (Per $1K Revenue)

★★★★★
BMEZ generates approximately $1,000 of gross profit, $39 of operating income, and $2,722 of free cash flow for every $1,000 of revenue. Based on FY2024 results. Solid margins and strong cash conversion support the rating, although capital efficiency remains weak.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
BMEZ has a relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Portfolio Investment IncomeDividends and interest received from underlying healthcare, pharmaceutical, and medical device equities.The fund earns baseline cash flow from the dividends paid by the companies it owns.
Option Premium GenerationCash premiums collected from writing covered call options on selected portfolio securities.Additional income is generated by selling call options against portions of the equity portfolio.

Valuation

Trailing PE 5.07
Forward PE -
Enterprise Value -
Price to Sales(TTM) 5.03
Enterprise Value -
Price to Sales(TTM) 5.03
Enterprise Value to Revenue 5.03
Enterprise Value to EBITDA -
Shares Outstanding 62.50M
Shares Floating -
Shares Outstanding 62.50M
Shares Floating -
Percent Insiders 0.02
Percent Institutions 28.16

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.